OverviewDosage GuideSide EffectsProtocolResultsWeight LossClinical TrialsInjection GuideGLP-3How to GetCostFDA ApprovalAvailabilityTelehealthLiver FatMuscle LossWhere to Buy
Semaglutide Protocol Guide
A structured protocol for using Semaglutide: cycle length, administration timing, stacking considerations, and monitoring.
Protocol Overview
Recommended Cycle Length
12–52 weeks (chronic use)
Dosing Frequency
Once weekly (injectable); once daily (Rybelsus oral)
Administration Route
Subcutaneous injection (abdomen, thigh, upper arm)
Titration Required
Yes — see schedule
Week-by-Week Titration Protocol
1
Week
0.25mg
Starting dose — monitor for side effects
5
Week
0.5mg
Increase if previous dose was well-tolerated
9
Week
1mg
Increase if previous dose was well-tolerated
13
Week
1.7mg
Increase if previous dose was well-tolerated
17
Week
2.4mg
Maximum / maintenance dose
Stacking & Combination Protocols
Important: Stacking Semaglutide with other active compounds significantly increases the complexity of managing side effects and monitoring. Always consult a qualified healthcare provider before combining compounds.
Commonly Discussed Combinations
Cagrilintide
Research only — no approved combination existsAmylin analogue — Cagrisema (cagrilintide + semaglutide) trials show additive satiety effects. In theory, combining with Semaglutide could further enhance weight loss through complementary mechanisms.
Synergy: High potential
MOTS-c
Research onlyMitochondrial-derived peptide that may enhance metabolic efficiency and fat oxidation. Believed to complement GLP-1 class drugs by addressing insulin resistance at the cellular level.
Synergy: Theoretical
CJC-1295 / Ipamorelin
Anecdotal onlyGrowth hormone secretagogues. Sometimes used alongside weight-loss peptides for lean mass preservation during aggressive caloric restriction. No clinical data on combination with Semaglutide.
Synergy: Low / off-protocol
Do NOT Stack With
✗
Other GLP-1 agonists (semaglutide, tirzepatide)
Redundant mechanism, significantly elevated GI side effect risk, no clinical rationale
✗
Other GLP-1/GIP dual or triple agonists
Same receptor targets — additive side effects without additive benefit
✗
Insulin (without medical supervision)
Hypoglycemia risk — if diabetic and on insulin, dose reduction is required under medical guidance
Related Peptides
tirzepatide— commonly compared / discussed alongside Semaglutide
Learn more →retatrutide— commonly compared / discussed alongside Semaglutide
Learn more →ipamorelin— commonly compared / discussed alongside Semaglutide
Learn more →Monitoring While on Protocol
- ✓Track body weight weekly
- ✓Monitor blood glucose if diabetic or pre-diabetic
- ✓Check lipid panel and liver enzymes at baseline and every 3 months
- ✓Document side effects and dose response in a log
- ✓Schedule follow-up with prescribing provider every 4–8 weeks initially
Exploring Retatrutide Access?
See how patients are accessing retatrutide through physician-supervised telehealth and compounding pharmacies.
Not FDA approved. Access requires physician oversight.
Affiliate links — we may earn a commission at no cost to you.
Medical Disclaimer: This protocol guide is for informational purposes only and is based on available research. It does not constitute medical advice. Work with a licensed healthcare provider to design and monitor your peptide protocol.